Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Urogen Pharma Ltd (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 506,312
  • Shares Outstanding, K 13,751
  • Annual Sales, $ 1,130 K
  • Annual Income, $ -75,660 K
  • 60-Month Beta 1.48
  • Price/Sales 457.76
  • Price/Cash Flow N/A
  • Price/Book 5.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -1.21
  • Number of Estimates 5
  • High Estimate -0.59
  • Low Estimate -1.74
  • Prior Year -0.88
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.61 +2.48%
on 03/08/19
42.32 -16.19%
on 02/25/19
-5.87 (-14.20%)
since 02/22/19
3-Month
34.61 +2.48%
on 03/08/19
55.49 -36.08%
on 01/08/19
-7.05 (-16.58%)
since 12/21/18
52-Week
34.61 +2.48%
on 03/08/19
69.57 -49.02%
on 05/21/18
-18.83 (-34.68%)
since 03/22/18

Most Recent Stories

More News
UroGen Pharma to Present at March 2019 Investor Conferences

UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March:

URGN : 35.47 (-3.67%)
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results

--Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020

URGN : 35.47 (-3.67%)
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the market. The...

URGN : 35.47 (-3.67%)
Factors of Influence in 2019, Key Indicators and Opportunity within Toyota Motor, UROGEN PHARMA, Macerich, Cosan, Middlesex Water, and Howard Hughes -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Toyota Motor Corporation...

CZZ : 12.06 (-7.44%)
HHC : 107.79 (-2.92%)
URGN : 35.47 (-3.67%)
TM : 120.22 (-0.18%)
MSEX : 56.52 (-3.55%)
MAC : 43.78 (-0.07%)
UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 35.47 (-3.67%)
JPM : 99.76 (-3.02%)
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 35.47 (-3.67%)
JPM : 99.76 (-3.02%)
UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

--All Evaluated Patients in CR Remain Disease Free at Six Months

URGN : 35.47 (-3.67%)
UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 35.47 (-3.67%)
UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

--Submission Supported by Pivotal Phase 3 OLYMPUS Study; Topline Results to be Presented in January 2019

URGN : 35.47 (-3.67%)
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments

Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA)...

URGN : 35.47 (-3.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade URGN with:

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

2nd Resistance Point 38.24
1st Resistance Point 37.53
Last Price 35.47
1st Support Level 36.41
2nd Support Level 36.00

See More

52-Week High 69.57
Fibonacci 61.8% 56.22
Fibonacci 50% 52.09
Fibonacci 38.2% 47.96
Last Price 35.47
52-Week Low 34.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar